Updated Aug 10 at 6:03pm ET.
Follow Insulet to never miss an important update.
Law firms are seeking lead plaintiffs for a class action lawsuit against Insulet. The suit alleges the company made false claims about its manufacturing quality while actually producing about 7 million pods that required safety corrections due to risks of delivering too little insulin.
While these types of lawsuits are common after a stock price drop, this one points to specific product recalls that could damage the company's reputation with doctors and patients. For a business built on the safety and reliability of a wearable medical device, any sustained doubt about manufacturing standards is a risk to long-term growth.
Source: Business Wire
Truist Securities downgraded the stock to Hold from its previous rating. This move follows Insulet's decision to lower its full-year sales growth forecast, which has raised concerns about a slowdown in the U.S. market for insulin pumps. Analysts often move to a Hold rating when they believe the stock lacks a clear reason to rise in the near future.
Wells Fargo lowered its rating to Equal Weight, which is essentially a Neutral view. The firm is reacting to the company's warning that sales growth in the second half of the year will be slower than previously expected. When multiple analysts downgrade at once, it often reflects a shift in the broader market's expectations for how fast the company can grow.
Insulet reported earnings of $1.66 per share, which was better than the $1.47 analysts expected. Revenue grew about 23 percent to $802 million, also topping expectations. International sales were a bright spot, growing more than 30 percent as the company expands its reach outside the U.S.
However, the company lowered its sales growth forecast for the rest of the year, citing a softer market for its Omnipod pumps in the United States. This suggests that while the company is still growing, the pace of new patients switching to its tubeless system may be hitting a speed bump. The stock fell more than 12 percent following the news.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
A securities class action lawsuit has been filed against Insulet, alleging the company made misleading statements about its manufacturing controls and the safety of its Omnipod system. The claims focus on whether management concealed the full scope of defects in the cannula, the small tube that delivers insulin, which reportedly caused delivery failures in some devices.
While law firms often file these suits after a stock drop to seek damages for investors, the underlying allegations about manufacturing quality are worth watching. Insulet’s business relies on the high-volume production of disposable pods. If systemic production issues are proven, it could lead to higher costs or damage the trust of the patients and doctors who choose these pumps for daily diabetes management.
Source: GlobeNewsWire
Analysts recently downgraded the stock and slashed their price targets following the company's latest earnings report. Most analysts still rate the stock a buy, and the average target of $185 suggests a 30% upside from today's price.
The company has a perfect record of beating expectations over the last two years. Management consistently sets a bar they can clear, even as the business grows rapidly.
| Expectation | |
|---|---|
| EPS | $1.59 |
| Revenue | $835M |
